AOA
0.002
100%
CCO
0.001
-50%
KME
0.685
52.2%
AOK
0.002
-33.3%
ARO
0.003
50%
RGT
0.037
-32.7%
XEN
0.003
50%
LOT
0.255
-26.1%
FAU
0.007
40%
1AD
0.003
-25%
YUG
0.048
33.3%
AS2
0.006
-25%
MEG
0.022
29.4%
CUL
0.006
-25%
DWG
0.15
25%
VFX
0.045
-22.4%
LSR
0.01
25%
BIM
0.1
-20%
PCL
0.01
25%
MAY
0.004
-20%
XGL
0.01
25%
OVT
0.004
-20%
RTH
0.72
24.1%
KLR
0.081
-19%
HMG
0.185
23.3%
CAY
0.05
-16.7%
PWN
0.012
20%
EXT
0.005
-16.7%
SFX
0.044
18.9%
MVL
0.01
-16.7%
B4P
1.6
18.5%
TXR
0.005
-16.7%
AN1
0.007
16.7%
AYA
4
-16.1%
NAG
0.007
16.7%
BMM
0.056
-15.2%
ZEU
0.007
16.7%
AON
0.034
-15%
AAL
0.27
14.9%
AAU
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759